BioSpace News Archive

LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it has appointed senior finance executive Jeffrey A. Davis, current CFO of Qurate Retail Group and former CFO of J. C. Penney Company Inc., to its board of directors effective Dec. 1

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that the company’s management is scheduled to participate in the upcoming Piper Jaffray Healthcare Conference at the Lotte New York Palace Hotel in New York City.

Agilent Technologies Inc. (NYSE: A) announced today that it has received two Life Science Industry Awards (LSIA) for ‘Most Innovative New Products in 2019’ from BioInformatics Inc.

Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2019 at 2:30 p.m. Eastern Time.

Knight Therapeutics Inc. (TSX: GUD) (“Knight”) and TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD”) announced today that Knight’s New Drug Submission (NDS) for BIJUVA® has been accepted for review by Health Canada. BIJUVA, estradiol and progesterone capsules, is licensed by Knight from TherapeuticsMD

AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 31st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2019 at 4:30 p.m. Eastern Time.

BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present at the Piper Jaffray 31st Annual Healthcare Conference being held December 3 – 5, 2019 in New York City.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Richard Rubino, Chief Financial Officer, will present in a fireside discussion at the Piper Jaffray 31st Annual Healthcare Conference

POXEL SA (Euronext – POXEL – FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes, announced today positive topline Phase 3 results from the 36-week, open-label extension period of the TIMES 3 trial, which evaluated Imeglimin in combination with insulin for the treatment of type 2 diabetes

Moore led development of one of only two FDA-approved CAR-T therapies.